Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.62 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818584 | 0.95 | TLR8 (0.68) | TLR8IKBKBKMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5480918 | 0.94 | TLR8 (0.66) | TLR8IKBKBKMT2AKDM4EALDH1A1 | |
| SCHEMBL9242375 | 0.79 | TLR8 (0.48) | TLR8MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16848237 | 0.77 | TLR8 (1.00) | TLR8IKBKBBACE1KDM4EALDH1A1 | |
| SCHEMBL8213737 | 0.77 | TLR8 (0.49) | TLR8MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8672800 | 0.77 | TLR8 (0.49) | TLR8MEN1NPC1RAB9AKMT2A | |
| SCHEMBL317873 | 0.76 | TLR8 (0.60) | TLR8IKBKBMEN1NPC1RAB9A | |
| SCHEMBL1019128 | 0.76 | TLR8 (0.70) | TLR8IKBKBMEN1NPC1RAB9A | |
| SCHEMBL7191719 | 0.76 | TLR8 (0.48) | TLR8MEN1NPC1RAB9AKMT2A | |
| SCHEMBL317874 | 0.74 | TLR8 (0.62) | TLR8IKBKBMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092488-A1 | Quninoline Methanol Compounds for the Treatment and Prevention of Parasitic Infections | DOW GEOFFREY | 2011-04-21 | — | — | US | disclosed |
| WO-2008060269-A2 | QUINOLINE METHANOL COMPOUNDS FOR THE TREATMENT AND PREVENTION OF PARASITIC INFECTIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092488-A1 | Quninoline Methanol Compounds for the Treatment and Prevention of Parasitic Infections | MTX1, MTX2, NQO2 | TLR8 1003/4885IKBKB 4233/4885BACE1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.